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Abstract
Senescence secretome was recently reported to promote liver cancer in an obese mouse
model. Steatohepatitic hepatocellular carcinoma (SH-HCC), a new variant of HCC, has
been found in metabolic syndrome patients, and pericellular fibrosis, a characteristic feature
of SH-HCC, suggests that alteration of the tumor stroma might play an important role in SH-
HCC development. Clinicopathological characteristics and tumor stroma showing senes-
cence and senescence-associated secretory phenotype (SASP) were investigated in 21
SH-HCCs and 34 conventional HCCs (C-HCCs). The expression of α-smooth muscle actin
(α-SMA), p21Waf1/Cif1, γ-H2AX, and IL-6 was investigated by immunohistochemistry or
immunofluorescence. SH-HCCs were associated with older age, higher body mass index,
and a higher incidence of metabolic syndrome, compared to C-HCC (P <0.05, all). The num-
bers of α-SMA-positive cancer-associated fibroblasts (CAFs) (P = 0.049) and α-SMA-posi-
tive CAFs co-expressing p21Waf1/Cif1 (P = 0.038), γ-H2AX (P = 0.065), and IL-6 (P = 0.048)
were greater for SH-HCCs than C-HCCs. Additionally, non-tumoral liver from SH-HCCs
showed a higher incidence of non-alcoholic fatty liver disease and a higher number of α-
SMA-positive stellate cells expressing γ-H2AX and p21Waf1/Cif1 than that from C-HCCs
(P <0.05, all). In conclusion, SH-HCCs are considered to occur more frequently in metabolic
syndrome patients. Therein, senescent and damaged CAFs, as well as non-tumoral stellate
cells, expressing SASP including IL-6 may contribute to the development of SH-HCC.
Introduction
As in Western countries, the prevalence of metabolic syndrome is rapidly increasing in Asia,
including Korea [1, 2]. Metabolic syndrome induces non-alcoholic fatty liver disease (NAFLD),
which encompasses a broad spectrum of conditions, ranging from simple steatosis to non-
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alcoholic steatohepatitis, and ultimately cirrhosis [3] Metabolic syndrome patients are report-
edly at twice as high a risk for hepatocellular carcinoma (HCC) than normal individuals [4].
Moreover, diabetes and obesity, two major components of metabolic syndrome, increase the
risk of HCC in chronic B or C viral patients by approximately 100-fold [5]. Recently, a histologi-
cally distinct subtype of HCC showing features of steatohepatitis within tumor regions has been
pathologically characterized and introduced as a new HCC category, termed steatohepatitic
HCC (SH-HCC) [6–8]. The SH-HCC variant, which is characterized by large droplet steatosis,
pericellular fibrosis, inflammation, ballooning, and Mallory-Denk body formation, has been
reported to be associated with metabolic syndrome [6–8].
The biological behavior of cancers is influenced not only by neoplastic epithelial cells but
also by tumor stromal cells [9]. Cancer-associated fibroblasts (CAFs) (also known as myofibro-
blasts), a component of the tumoral stroma, have been reported to promote tumor growth,
invasion, and angiogenesis. Aggressive biologic behavior and dismal prognosis have also been
demonstrated various cancers with abundant CAFs, including HCCs [10–12]. One distinctive
pathologic feature of SH-HCC is pericellular fibrosis, compared to conventional HCCs
(C-HCCs), which usually show little or no stromal fibrosis. Accordingly, the moleculo-patho-
logical characteristics of the tumor stroma in SH-HCCs might be different from that in
C-HCCs.
Cellular senescence encompasses a complex biological process of tumor progression, tumor
suppression, aging, and tissue repair. Senescent cells develop a senescence-associated secretory
phenotype (SASP) that can affect the behavior of neighboring cells [13]. Reportedly, dietary-
and genetically-induced obese mice show enhanced liver inflammation and tumorigenesis
promoted by IL-6 [14]. More recently, SASP in hepatic stellate cells (HSCs), along with secre-
tion of various inflammatory and tumor-promoting factors, was found to contribute to HCC
development in obese mice [15].
In the present study, we aimed to investigate alterations of the tumor stroma in SH-HCCs,
comparing the expression of CAFs, HSCs, senescence-associated proteins, and SASP factors
(p21Waf1/Cif1, γ-H2AX, and IL-6) between SH-HCCs and C-HCCs.
Materials and methods
Case selection and clinicopathologic evaluation
We reviewed the pathological and clinical records of consecutive HCC patients who under-
went partial hepatectomy or liver transplantation between 2009 and 2014 from the archives of
the Department of Pathology, Yonsei University College of Medicine. This study was approved
by the Institutional Review Board of Severance Hospital, Yonsei University College of Medi-
cine, and the need for patient consent was waived (4-2012-0649). Patients who underwent pre-
operative chemotherapy or locoregional therapy (such as transarterial chemoembolization or
radioactive frequency ablation) were excluded. We also excluded patients with a history of
excessive alcohol consumption (defined as>40 g/day). Representative formalin-fixed, paraf-
fin-embedded (FFPE) tissue sections stained with hematoxylin-eosin and Masson’s trichrome
were reviewed for all cases.
The SH-HCCs included in this study showed at least four of the following features in50%
of the tumor area: 1) large-droplet fat within the tumor; 2) ballooning change; 3) Mallory-
Denk bodies; 4) pericellular fibrosis with a “chicken-wire” appearance; and 5) inflammation,
including infiltration of neutrophils and lymphocytes (Fig 1A–1D). The presence or absence
of Mallory-Denk bodies was evaluated by immunoreactivity for ubiquitin. For comparison,
C-HCCs with the typical histopathological features of HCC were selected (Fig 1E and 1F).
Other histopathological features including size, grades of differentiation, and presence of
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microvascular invasion were evaluated in each HCC. Matching non-neoplastic liver tissue
from each case was examined for the presence of NAFLD or chronic hepatitis [16].
Medical records were reviewed to check for the presence of the following metabolic syn-
drome risk factors: central obesity (waist circumference>90 cm in men and>80 cm in
women), hypertriglyceridemia (serum triglycerides150 mg/dLor current use of antidyslipi-
demic medication), low high-density lipoprotein cholesterol (<40 mg/dL in men and<50 mg/
dL in women), diabetes (elevated fasting plasma glucose levels100 mg/dL or current use of
anti-diabetic medication), and hypertension (systolic blood pressure130 mmHg or diastolic
blood pressure85 mmHg or current use of blood pressure medication). According to the US
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III, 2001) and
International Diabetes Federation criteria, metabolic syndrome was defined by at least two of
the following: central obesity, low high-density lipoprotein cholesterol, diabetes, hypertension,
and hypertriglyceridemia [17, 18]. Serum hepatitis B virus (HBV) surface antigen (HBsAg) sta-
tus, anti-hepatitis C virus (HCV), and body mass index (BMI) were also reviewed.
Immunohistochemistry and immunofluorescence
Immunohistochemistry and immunofluorescence for α-smooth muscle actin (SMA),
p21Waf1/Cip1, γ-H2AX, IL-6, Ki-67, and ubiquitin were performed using representative sec-
tions of FFPE. The complete details of the primary antibodies used are presented in Table 1.
Immunohistochemistry was performed using an Envision kit (Dako, Glostrup, Denmark)
according to the manufacturer’s instructions. For double immunohistochemistry, the first
primary antibody was detected using a Vector Blue Alkaline Phosphatase Substrate Kit III
Fig 1. Pathological features of the steatohepatitic hepatocellular carcinoma (SH-HCC) and conventional HCC (C-HCC). A-D)
Representative images of SH-HCC showing (A) large-droplet steatosis, (B) ballooning change with Mallory-Denk bodies (inset: Mallory-Denk
bodies demonstrated by immunohistochemical stain for ubiquitin), (C) pericellular fibrosis in a chicken-wire pattern, and (D) lymphocytic infiltration.
E-F) Representative images of C-HCC without steatosis or fibrosis (A, B, D, E, H-E; C, F, Masson’s trichrome, original magnification x200; inset (B),
immunohistochemical stain for ubiquitin, original magnification x400).
doi:10.1371/journal.pone.0171922.g001
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(SK-5300; Vector Laboratories, Burlingame, CA), while the second primary antibody was
detected using Dako Envision kit (Dako) and then developed with 3,3-diaminobenzidine.
For double immunofluorescence, Alexa fluor 594 (red) goat anti-rabbit IgG and Alexa fluor
488 (green) donkey anti-mouse IgG conjugated antibodies (Invitrogen, Carlsbad, CA) were
used. Nuclei were stained with 4’-6’ diamidino-2-phenylindole (DAPI) (Molecular probe,
Gaithersburg, MD).
The number of α-SMA-positive CAFs or α-SMA-positive HSCs was counted in 20 randomly
selected, high-power fields (x400 magnification). The percentage of CAFs or HSCs co-expressing
p21Waf1/Cip1 and α-SMA was calculated by dividing the total number of p21Waf1/Cip1 and α-SMA
co-stained cells by the total number of α-SMA-positive cells and multiplying by 100%. The per-
centage of CAFs or HSCs co-expressing γ-H2AX/α-SMA, IL-6/α-SMA and Ki-67/α-SMA were
evaluated similarly. For IL-6, the staining intensity was graded on a scale of 0–3 (0, negative; 1,
weakly positive; 2, moderately positive; and 3, strongly positive), and the extent of distribution
was rated on a scale of 0–4 (0, expression in<5% of cells; 1, 5–25%; 2, 26–50%; 3, 51–75%; and
4, 76–100%). Histoscores were calculated as the sum of the intensity and distribution scores. Pos-
itive expression was defined as a histoscore of 4–7; a score of 0–3 was regarded as negative.
For tumoral and non-tumoral hepatocytes, the histoscores for p21Waf1/Cip1, γ-H2AX, and
Ki-67 labeling indices (LIs) were calculated as the percentage of positively stained nuclei, and
at least 1000 cells were counted in random areas of tissue sections.
DNA extraction and HBV DNA nested PCR
To detect occult HBV infection, the liver tissues of 20 patients who were negative for serum
HBsAg were analyzed by HBV DNA-nested PCR. Total DNA was extracted from 15 snap fro-
zen liver tissues using a Qiagen QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and from
five FFPE liver tissues using a ReliaPrep™ FFPE gDNA Miniprep System (Promega, Madison,
WI) according to the manufacturers’ instructions. Four different in-house, nested-PCR ampli-
fication assays were applied to detect PreS-S, Precore–core, Pol, and X HBV genomic regions
of HBV. We considered a case to be positive for HBV DNA when at least two different viral
genomic regions were detected [19]. The primer sets and PCR conditions are listed in S1
Table. PCR was performed with the AccuPower PCR Premix (Bioneer, Daejeon, Korea), con-
taining 10 pM of primers and 250 ng of genomic DNA.
Statistical analyses
Data were analyzed using SPSS software, version 20 (SPSS Inc., Chicago, IL). Differences between
groups were analyzed using Student’s t-test, χ2-test, and Fisher’s exact test, as deemed appropriate.
Table 1. List of antibodies used for immunohistochemistry and immunofluorescence.
Antibody Source Dilution Antigen retrieval
α-SMA (mouse mAb; 1A4) Dako (Glostrup, Denmark) 1:1000 Microwave, citrate (pH 6.0)
α-SMA (rabbit pAb) Abcam (Cambridge,UK) 1:300 Microwave, citrate (pH 6.0)
p21Waf1/Cip1 (rabbit mAb; 12D1) Cell signaling (Danvers, MA) 1:50 Microwave, citrate (pH 6.0)
γ-H2AX (rabbit mAb; 20E3) Cell signaling (Danvers, MA) 1:150 Microwave, citrate (pH 6.0)
IL-6 (rabbit pAb) Abcam (Cambridge, UK) 1:100 Protease K
Ki-67 (mouse mAb; MIB-1) Dako (Glostrup, Denmark) 1:100 Microwave, citrate (pH 6.0)
Ubiquitin (rabbit pAb) Dako (Glostrup, Denmark) 1:200 Automated immunostainer
Abbreviations: α-SMA, α-smooth muscle actin; mAb, monoclonal antibody; pAb, polyclonal antibody.
doi:10.1371/journal.pone.0171922.t001
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Univariable survival analyses were performed for overall and disease-free survival using Kaplan-
Meier’s method and log-rank tests. Statistical significance was reached when P<0.05, and P<0.1
was reported as a trend.
Results
Clinicopathological characteristics of steatohepatitic HCC
The clinical features of twenty-one cases of SH-HCCs and 34 cases of C-HCCs are summarized
in Table 2. Patients with SH-HCC showed significantly older age and higher BMI, compared to
C-HCC patients (P = 0.003 and P = 0.027, respectively). Central obesity, diabetes, and hypertrigly-
ceridemia were more frequently seen in SH-HCC patients than in C-HCC patients (P<0.05, all),
and metabolic syndrome was more frequently found in SH-HCC patients (n = 15, 71.4%) than in
C-HCC patients (n = 14, 41.2%) (P = 0.029). Chronic HBV infection was present in 15 (71.4%)
SH-HCCs and 29 (85.3%) C-HCCs, including occult HBV infection (4 cases in SH-HCCs and 5
cases in C-HCCs), and there was no significant difference between the two groups. Most patients
with metabolic syndrome also showed chronic HBV infection: 73.3% (11/15) of SH-HCCs and
78.6% (11/14) of C-HCCs. Among those with chronic HBV infection, four cases (4/15, 26.7%) of
SH-HCCs and 18 cases (18/29, 62.1%) of C-HCCs showed HBV infection only without metabolic
syndrome. Anti-HCV was not present in any patient from either group.
Table 2. Clinicopathological charaterisitcs of the steatohepatitic and conventional hepatocellular carcinoma patients.
SH-HCC (n = 21) C-HCC (n = 34) P value*
Age (years)a 66.7 ± 8.4 58.5 ± 10.1 0.003
Sex (male:female) 8:13 18:16 0.284
Body mass index (kg/m2) a 26.0 ± 4.6 23.7 ± 2.7 0.027
Central obesity 12 (57.1%) 11 (32.4%) 0.012
Low HDL cholesterol 5 (23.8%) 5 (14.7%) 0.387
Diabetes 12 (57.1%) 10 (29.4%) 0.041
Hypertension 10 (47.6%) 14 (41.2%) 0.640
Hypertriglyceridemia 5 (23.8%) 1 (2.9%) 0.028
Metabolic syndrome 15 (71.4%) 14 (41.2%) 0.029
Chronic HBV infection 15 (71.4%) 29 (85.3%) 0.300
Serum HBsAg (+) 11 (52.4%) 24 (70.6%) 0.392
Occult HBV infection 4 (19.1%) 5 (14.7%) 0.674
Tumoral pathology
Tumor size (cm)a 3.3 ± 1.5 4.2 ± 3.5 0.308
Differentiation
Ⅰ 2 (9.5%) 0 (0.0%) 0.086
Ⅱ 11 (52.4%) 12 (35.3%)
‘ Ⅲ 8 (38.1%) 21 (61.8%)
Ⅳ 0 (0.0%) 1 (2.9%)
Microvessel invasion 8 (38.1%) 15 (44.1%) 0.660
Non-tumor pathology
NAFLD alone 4 (19.0%) 2 (5.9%) 0.001
NAFLD with chronic hepatitis 14 (66.7%) 10 (29.4%)
Chronic hepatitis alone 3 (14.3%) 22 (64.7%)
Abbreviations: HDL, high-density lipoprotein; HBV, hepatitis B virus; HBsAg, hepatitis B virus surface antigen; NAFLD, non-alcoholic fatty liver disease.
* Fisher’s exact test, Pearson chi-square and Student’s t-test. Statistically significant P values are expressed in bold font.
a Mean ± standard deviation.
doi:10.1371/journal.pone.0171922.t002
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The pathological features of the SH-HCCs and C-HCCs are summarized in Table 2. Tumor
size, differentiation, and microvascular invasion were not significantly different between the
two HCC groups. In the non-neoplastic livers, NAFLD was more frequently found in
SH-HCCs than in C-HCCs (P = 0.001). NAFLD was noted in 18 (85.7%) SH-HCC patients,
including four cases of NAFLD alone and 14 cases of NAFLD with co-existing chronic hepati-
tis. In contrast, the background liver of C-HCCs showed NAFLD in 12 cases (35.3%), includ-
ing two cases of NAFLD alone and 10 cases of NAFLD with co-existing chronic hepatitis.
Expressions of p21Waf1/Cip1, γ-H2AX, and IL-6 in tumoral regions of
steatohepatitic HCC vs. conventional HCC
A significantly greater number of α-SMA-positive CAFs were seen in tumoral regions of SH-
HCCs, compared to C-HCCs (mean ± SD: 295.4 ± 100.47 for SH-HCCs and 233.9 ± 111.56 for
C-HCCs per 20 high-power fields, P = 0.049) (Fig 2A). The expression status of the senescence
marker p21Waf1/Cip1 and DNA damage marker γ-H2AX was evaluated in CAFs. The percentage
of CAFs co-expressing nuclear p21Waf1/Cip1 and cytoplasmic α-SMA was significantly higher in
SH-HCCs than in C-HCCs (5.9 ± 4.69% vs. 4.2 ± 5.36%, P = 0.038) (Fig 2B). The percentage of
CAFs co-expressing nuclear γ-H2AX and cytoplasmic α-SMA also tended to be higher in SH-HCCs
than in C-HCCs (27.3 ± 16.50% vs. 19.2 ± 15.43%, P = 0.065) (Fig 2C). There were no significant
differences in the proliferative activity of CAFs (reflected by the co-expression of nuclear Ki-67 and
cytoplasmic α-SMA) between the two groups (4.6 ± 4.89% vs. 3.9 ± 4.13%, P = 0.775) (Fig 2D). IL-6
expression was mainly found in tumoral stroma, and was more highly expressed in SH-HCCs than
in C-HCCs (P = 0.033) (Fig 2E). In addition, double immunofluorescence staining for IL-6 and α-
SMA revealed co-expression of IL-6/α-SMA in 29.3 ± 33.61% and 7.0 ± 14.10% of CAFs in SH-
HCCs and C-HCCs, respectively; this was a statistically significant difference (P = 0.048) (Fig 2F).
Taken together, these findings indicate that damaged and senescent CAFs expressing IL-6 are more
common in SH-HCCs than in C-HCCs.
Additionally, we evaluated expression of p21Waf1/Cip1 and γ-H2AX in tumoral hepatocyte-
like epithelial cells of SH-HCCs and C-HCCs, and there was no significant difference in
p21Waf1/Cip1 and γ-H2AX LIs. There was also no significant difference in Ki-67 LIs between
the tumoral hepatocyte-like epithelial cells of SH-HCCs and C-HCCs (S1A–S1C Fig).
Expressions of p21Waf1/Cip1, γ-H2AX, and IL-6 in non-tumoral regions of
steatohepatitic HCC vs. conventional HCC
In non-tumoral regions, the numbers of α-SMA-expressing non-tumoral HSCs (per 20 high-
power fields) were 167.7 ± 95.81 (mean ± SD) and 144.8 ± 125.50 in SH-HCCs and C-HCCs,
respectively, and the difference was not statistically significant (P = 0.358) (Fig 3A). The per-
centage of non-tumoral HSCs co-expressing nuclear p21Waf1/Cip1 and cytoplasmic α-SMA was
significantly higher in non-tumoral regions of SH-HCCs than those of C-HCCs (2.0 ± 2.42%
vs. 0.7 ± 1.44%, P = 0.019) (Fig 3B). The percentage of HSCs co-expressing γ-H2AX and α-
SMA was also higher in non-tumor regions of SH-HCCs than those of C-HCCs (7.6 ±7.01%
vs. 3.8 ± 3.16%, P = 0.023) (Fig 3C). Co-expression of Ki-67 and α-SMA was very rarely found
in non-tumoral HSCs, without significant differences between the two groups (0.8 ± 1.24% vs.
1.1 ± 1.28%, P = 0.683) (Fig 3D). The expression of IL-6 was mainly found in the stroma of
portal tracts and fibrous septa of non-tumoral regions, and although not statically significant,
was relatively highly expressed in SH-HCCs than in C-HCCs (P = 0.065) (Fig 3E). The per-
centage of non-tumoral HSCs that co-expressed IL-6 and α-SMA was very low, and showed
no significant difference between the two HCC groups (5.4 ± 5.90% vs. 4.0 ± 5.34%, P = 0.299)
(Fig 3F).
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Fig 2. Cancer-associated fibroblasts (CAFs) expressing p21Waf1/Cip1, γ-H2AX, and IL-6 in tumoral regions
of steatohepatitic hepatocellular carcinomas (SH-HCCs) and conventional HCCs (C-HCCs). A) CAFs
expressing α-SMA are more frequently found in SH-HCCs than in C-HCCs. B) Double immunohistochemical stain
demonstrates nuclear p21Waf1/Cip1 in blue and cytoplasmic α-SMA in brown. CAFs co-expressing p21Waf1/Cip1 and
α-SMA are more frequently seen in SH-HCCs than in C-HCCs. (C) Double immunofluorescence images of γ-
H2AX (red) and α-SMA (green). CAFs co-expressing γ-H2AX and α-SMA are relatively higher in SH-HCCs than
Steatohepatitic hepatocellular carcinoma
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Non-tumoral hepatocytes were also evaluated for p21Waf1/Cip1, γ-H2AX, and Ki-67 LIs, and
no significant differences were seen in the expression of these markers between SH-HCCs and
C-HCCs (P>0.05 for all) (S1D–S1F Fig).
Survival analysis of steatohepatitic and conventional HCCs
The median follow-up time after surgical resection was 30.5 months (range, 1–73), and one
patient with C-HCC who underwent liver transplantation was excluded from the survival anal-
ysis. Kaplan-Meier plots revealed no significant differences between SH-HCCs (n = 21) and
C-HCCs (n = 33) in both disease-free (P = 0.602) and overall survival (P = 0.709) (S2 Fig).
Discussion
Recently, a histologically distinct subtype of HCC, termed SH-HCC has been introduced and
one of distinctive pathologic features of SH-HCC is pericellular fibrosis. In this study, α-SMA-
positive CAFs, which are considered to contribute to pericellular fibrosis, were more frequent
in the tumoral regions of SH-HCCs than those for C-HCCs. In addition, we found that mark-
ers of cellular senescence, p21Waf1/Cip1, and DNA damage, γ-H2AX, are more highly expressed
in CAFs from SH-HCCs than those from C-HCCs. In contrast, the proliferative activity of
CAFs showed no significant difference between two groups. Thus, our results suggested that
senescent and damaged CAFs might be important in the pathogenesis of SH-HCCs. Cellular
senescence was previously thought to be a barrier to tumorigenesis; however, recently, it has
also been reported to promote carcinogenesis. The DNA damage signaling pathway leads to
the activation of p53 tumor suppressor, which in turn may cause transient arrest of the cell
cycle in addition to DNA repair, and ultimately leading to cancer suppression [20]. In contrast,
loss of p53 activity in senescent or damaged fibroblasts enhances SASP, which can drive cancer
and aging [13]. An altered tissue microenvironment induced by senescent cells has been pro-
posed to contribute to increased cancer occurrence in old aged populations, and senescent
human fibroblasts were reported to promote proliferation and tumorigenesis of mutant epi-
thelial cells in an in vitro study [21]. Indeed, the patients with SH-HCCs were older than those
with C-HCCs in this study.
IL-6, one of SASP factors, is a pro-inflammatory signaling protein that encourages tumor
growth, and exerts its oncogenic activity by triggering downstream STAT-3 and ERK pathways
[14, 22]. In our study, IL-6 was mainly expressed in CAFs, and was more highly expressed in
SH-HCCs than in C-HCCs, suggesting that IL-6, induced by a senescent phenotype in CAFs,
may alter the tumor stroma, which is important in the development of SH-HCCs. IL-6 is also
known to be associated with metabolic disorders, and has been found to be up-regulated in
NAFLD and obesity-related HCC [14, 23].
In addition, we found NAFLD more often in the background liver of SH-HCC patients
than those from C-HCC patients. In non-neoplastic liver, HSCs undergo phenotypic conver-
sion from quiescent retinoid-storing cells to active myofibroblasts in response to stimuli,
including fatty change, reactive oxygen species generation, and DNA damage, and ultimately
affect fibrosis progression. In chronic liver disease, including NAFLD and chronic viral
in C-HCCs. (D) Double immunofluorescence images of Ki-67 (green) and α-SMA (red). There is no difference
between groups. (E) Greater expression of IL-6, detected by immunohistochemistry, in SH-HCCs than in
C-HCCs. (F) Double immunofluorescence of IL-6 (red) and α-SMA (green). Nuclei were stained with DAPI. CAFs
co-expressing IL-6 and α-SMA are significantly more abundant in SH-HCCs than in C-HCCs. The merged
fluorescence images of boxed areas are further magnified in the insets. Box plot graphs in the right column
demonstrate comparisons between the two groups (A-D, F, original magnification x400; E, original magnification
x200). α-SMA, α-smooth muscle actin.
doi:10.1371/journal.pone.0171922.g002
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Fig 3. Non-tumoral hepatic stellate cells (HSCs) expressing p21Waf1/Cip1, γ-H2AX, and IL-6 in non-
tumoral regions of SH-HCCs and C-HCCs. (A) Non-tumoral HSCs expressing α-SMA show no differences
in number between the two groups. (B) Double immunohistochemical stain reveals nuclear p21Waf1/Cip1 in
blue (arrow) and cytoplasmic α-SMA in brown. Non-tumoral HSCs co-expressing p21Waf1/Cip1 and α-SMA
are more frequently seen in non-tumoral regions of SH-HCCs compared to that for C-HCCs. (C) Double
immunofluorescence images of γ-H2AX (red) and α-SMA (green). Non-tumoral HSCs co-expressing γ-H2AX
Steatohepatitic hepatocellular carcinoma
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hepatitis, increased cytokine production from HSCs and immune cells has been reported to
promote hepatocarcinogenesis [11]. Interestingly, the expression of p21Waf1/Cip1 and γ-H2AX
in non-tumoral HSCs was significantly greater in SH-HCCs than in C-HCCs. Moreover,
expression of IL-6 was relatively higher in the background liver of SH-HCCs, compared to
C-HCCs. These findings suggest that the development of SH-HCC is also influenced by SASP
of senescent and damaged HSCs in the background liver with NAFLD.
Recently, several changes in the composition of the intestinal microbiomes of dietary- and
genetically-mutated obese mice have been demonstrated, and the changes have been shown to
lead to the production of deoxycholic acid, a secondary bile acid known to cause DNA dam-
age. This, in turn, provoked HSCs to undergo senescence and to produce SASP factors, such as
IL-6, ultimately leading to the development of HCC [15]. Our data of human SH-HCCs sup-
port this study. Therefore, senescent CAFs and HSCs with SASP, which are characteristic of
tumoral and non-tumoral stroma of SH-HCCs, are considered to be important in the develop-
ment of SH-HCCs, and they might be promoted by gut microbial metabolites in patients with
metabolic syndrome. Further study thereon is needed.
Previous studies have shown SH-HCC to be associated with metabolic syndrome [6–8],
and this study also revealed an association between SH-HCCs, higher body mass index, and a
higher incidence of metabolic syndrome, compared to C-HCC. SH-HCC has also been
reported in chronic C viral hepatitis patients with or without metabolic syndrome; however,
the association of SH-HCC with HBV, which is the main etiology of HCC in Asia, including
Korea, remains unclear [24]. The natural history of chronic HBV infection ranges from the
replicative phase with active liver disease (hepatitis B e antigen [HBeAg]-positive hepatitis) to
low or non-replicative phase with HBeAg seroconversion and remission of liver disease (inac-
tive carriers). Subsequently in some cases, spontaneous hepatitis B surface antigen (HBsAg)
seroclearance, which is regarded as a surrogate marker of resolved hepatitis B, may occur with
an estimated annual incidence of 0.1–2% with geographic variations. In the patients with
occult HBV infection after seroclearance of circulating HBsAg, HBV DNA is persistently
detected in the liver tissues, and the risk of HCC remains although necroinflammation is
markedly improved. Previously, our group reported that 5 of 49 (10.2%) patients with occult
HBV infection were noted to have HCC during a mean follow-up period of 19.6 months after
HBsAg seroclearance [25]. In this study, to thoroughly investigate the association between
SH-HCCs and HBV, we checked the serum HBsAg by reviewing medical record, and for the
patients with negative serum HBsAg, occult HBV infection was examined like followings: total
DNA was extracted from the liver tissues and four different nested-PCR amplification assays
were applied to detect PreS-S, Precore–core, Pol, and X HBV genomic regions of HBV. We con-
sidered to be positive for HBV DNA when at least two different viral genomic regions were
detected. In this study, the incidence of chronic HBV infection showed no significance difference
between SH-HCCs and C-HCCs, although the incidence of metabolic syndrome was higher in
SH-HCCs compared to C-HCCs. Actually, the majority of SH-HCCs (15/21, 71.4%) and
C-HCCs (29/34, 85.3%) showed chronic HBV infection. Among them, four SH-HCCs (4/15,
and α-SMA are higher in non-tumoral regions of SH-HCCs, compared to that for C-HCCs. (D) Double
immunofluorescence images of Ki-67 (green) and α-SMA (red) showing no difference between groups. (E) IL-
6 expression, detected by immunohistochemistry, is relatively higher in the stroma of non-tumoral regions of
SH-HCCs, compared to that for C-HCCs. (F) Double immunofluorescence of IL-6 (red) and α-SMA (green)
show no difference between groups. Nuclei were stained with DAPI. The merged fluorescence images of
boxed areas are further magnified in the insets. Box plot graphs in the right column demonstrate comparisons
between the two groups (A-D, F, original magnification x400; E, original magnification x200). α-SMA, α-
smooth muscle actin.
doi:10.1371/journal.pone.0171922.g003
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26.7%) and five C-HCCs (5/29, 17.2%) demonstrated occult HBV infection. In non-neoplastic
liver with occult HBV infection, all of four SH-HCCs showed NAFLD with chronic hepatitis,
and C-HCCs revealed two cases of NAFLD and three cases of NAFLD with chronic hepatitis,
where the necroinflammatory activity was low. Interestingly, four cases of SH-HCC in this study
showed HBV infection only without metabolic syndrome. Previous studies on transgenic mice
have shown that HBV protein X (HBx) can up-regulate lipogenic genes and promote steatosis
[26, 27]. Moreover, in HBx transgenic mice fed a high fat diet, fatty acid was found to stabilize
HBx protein and thereby promote steatohepatitis [28]. Therefore, HBV itself might be involved
in the lipogenesis of HCC, one of the main features of SH-HCC.
In conclusion, our results suggest that SH-HCC is a distinctive variant of HCC, which
develops more frequently in metabolic syndrome patients, and that senescent and damaged
CAFs, as well as non-tumoral stellate cells with SASP, including IL-6 expression, may contrib-
ute to the development of SH-HCC.
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